OpenBCI

OpenBCI occupies a distinctive position at the intersection of open-source neuroscience, research hardware, wearable biosensing, and human-computer interaction. Its core proposition is not a closed consumer device but a modifiable platform: researchers and developers can access raw physiological signals, adapt hardware configurations, and control downstream processing. The product range spans Cyton and Cyton + Daisy platforms, 3D-printable EEG headsets, and the Galea mixed-reality headset, which combines EEG, EMG, EDA, PPG, and eye tracking. That breadth differentiates OpenBCI from narrowly focused EEG wearables and from closed BCI systems that limit hardware or algorithm access. The company’s trade-off is that an open, research-oriented platform may require more technical expertise and integration work than turnkey products. With four recorded investors, a $200,000 disclosed 2024 round, and an estimated 11–50 employees, OpenBCI appears to be a small specialist platform competing through flexibility, affordability, and community accessibility rather than scale.

OpenBCI’s trajectory shows a long operating history followed by measured capital formation rather than a rapid, heavily financed expansion. Founded in February 2014, the company developed from a low-cost, programmable EEG platform into a broader biosensing business covering EEG, EMG, EKG, EDA, PPG, eye tracking, and mixed-reality interfaces. A venture round announced on Dec 15, 2021 established institutional backing, with BITKRAFT Ventures as lead investor and NaHCO3, Inertia Ventures, and re.Mind Capital also participating. The next recorded financing was an undisclosed round of $200,000 on Aug 28, 2024. The amount is modest relative to venture-backed peers, suggesting a capital-efficient or focused operating model, although revenue and runway data are unavailable. Product breadth is the clearest inflection point: Galea extends OpenBCI beyond standalone EEG into multimodal biometric sensing for augmented and virtual reality. Collaboration with unnamed US and Asia-Pacific research institutes in December 2024 signals continued research expansion. Hiring across six functional areas and the addition of Aarav Sharma in November 2024 indicate ongoing team development, while the listed employee range remains 11–50.